As Seen In

As Seen In
Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the...
As Seen In
Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) and YOFOTO Health Industry Co. Ltd. received approval from...
As Seen In
Canadian Technology and Innovation: making strides in the global cell therapy landscape
Another cell therapy rising star, RepliCel Life Sciences, is harnessing the healing properties of hair...
As Seen In
9 Challenges Keeping Cell And Gene Therapy Executives Up At Night
Despite recent progress in regenerative medicine, cell and gene therapy executives are still pioneering many...
As Seen In
Is the Age-Old Quest for a Baldness Cure Reaching Its End?
Click here to read the full article and interview as it appears in The New...
As Seen In
RepliCel's regenerative technology could take the "Polar Silk Road" to China
New opportunities are arising at every turn for the regenerative medicine community. READ ARTICLE ...
As Seen In
Regenerative Medicine Company's China Deal is 'Dramatically Transformational'
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance...
As Seen In
From stem cells to revenue: Bringing regenerative medicine to the masses
RepliCel lands Asian partnership to optimize the development of its biotech solutions for chronic conditions....
As Seen In
RepliCel CEO: Anticipating the Approval of Their Dermal Injector, its Impact in Europe and Beyond
Click here to read the full article and interview as it appears in Life Science:...
As Seen In
Japan is Fertile Ground for Biotech Deal
Click here to read the full article as it appears in the Streetwise Reports: The...
As Seen In
Company Uses Patients' Own Cells to Put an End to Baldness, Aging Skin and Tendon Degeneration
Company Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon...
As Seen In
Regenerative medicine: Interview with a game-changing leader
Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal...
As Seen In
Analyst Says Cell Therapy Company’s Move Decreases Risk
Click here to read the full article as it appears in the Streetwise Reports (08/23/17)....
As Seen In
Your Hair Follicles May Hold the Key to Younger Looking Skin
Click here to read the full article as it appears in the New York Daily...
As Seen In
Skin in the Game
To read the full article as it appears on DDN News (08/08/17), click here. ...
As Seen In
Why RepliCel May Be the Most Compelling Biotech Company to Watch in Canada
To read the brief and watch the interview provided by Market One Media Group as...
As Seen In
RepliCel Poised To Partner Up For Precision-Control Dermal Injector
To preview the interview with Tina Tan as it appears on Medtech.com, click here. (6/23/17)...
As Seen In
Hair-Raising R&D: RepliCel Developing Autologous Cell Therapy for Baldness
To read the full article as it appears on BioPharma-reporter.com, click here. (7/12/17) ...
As Seen In
Poised for Success with Positive Clinical Results
To read the full interview as it appears on Costmeticosbr.com.br, click here (7/6/17)....
As Seen In
A New Approach to Treating Hair Loss
To read the full interview as it appears on Technologyworks.com, click here. (6/27/17)...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.